Natus Medical Inc (BABY) Expected to Post Earnings of $0.42 Per Share

Wall Street analysts expect Natus Medical Inc (NASDAQ:BABY) to post earnings of $0.42 per share for the current fiscal quarter, according to Zacks Investment Research. Three analysts have issued estimates for Natus Medical’s earnings. The lowest EPS estimate is $0.42 and the highest is $0.43. Natus Medical posted earnings of $0.40 per share during the same quarter last year, which suggests a positive year over year growth rate of 5%. The firm is scheduled to announce its next earnings results before the market opens on Wednesday, October 24th.

According to Zacks, analysts expect that Natus Medical will report full-year earnings of $1.55 per share for the current fiscal year, with EPS estimates ranging from $1.54 to $1.56. For the next fiscal year, analysts expect that the company will post earnings of $1.81 per share, with EPS estimates ranging from $1.75 to $1.90. Zacks’ earnings per share averages are an average based on a survey of sell-side research firms that follow Natus Medical.

Natus Medical (NASDAQ:BABY) last announced its earnings results on Wednesday, July 25th. The medical equipment provider reported $0.35 EPS for the quarter, beating analysts’ consensus estimates of $0.26 by $0.09. The business had revenue of $130.70 million for the quarter, compared to analysts’ expectations of $130.60 million. Natus Medical had a negative net margin of 4.16% and a positive return on equity of 11.18%. The company’s quarterly revenue was up 7.0% on a year-over-year basis. During the same period in the previous year, the company posted $0.34 EPS.

Several brokerages have issued reports on BABY. BidaskClub cut shares of Natus Medical from a “buy” rating to a “hold” rating in a research note on Friday, July 13th. ValuEngine cut shares of Natus Medical from a “hold” rating to a “sell” rating in a research note on Wednesday, July 11th. Finally, Zacks Investment Research cut shares of Natus Medical from a “hold” rating to a “sell” rating in a research note on Friday, July 27th. Four equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $44.33.

In other news, Director Robert A. Gunst sold 9,100 shares of the company’s stock in a transaction on Friday, July 27th. The shares were sold at an average price of $34.11, for a total transaction of $310,401.00. Following the transaction, the director now directly owns 54,982 shares of the company’s stock, valued at approximately $1,875,436.02. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Robert A. Gunst sold 12,840 shares of the company’s stock in a transaction on Tuesday, July 31st. The stock was sold at an average price of $34.66, for a total transaction of $445,034.40. Following the transaction, the director now directly owns 54,982 shares in the company, valued at $1,905,676.12. The disclosure for this sale can be found here. Insiders sold a total of 77,540 shares of company stock worth $2,804,615 over the last three months. 5.50% of the stock is currently owned by corporate insiders.

Large investors have recently bought and sold shares of the company. Wells Fargo & Company MN grew its stake in shares of Natus Medical by 7.7% during the 2nd quarter. Wells Fargo & Company MN now owns 212,752 shares of the medical equipment provider’s stock worth $7,341,000 after purchasing an additional 15,208 shares during the period. Rhumbline Advisers grew its stake in shares of Natus Medical by 4.1% during the 2nd quarter. Rhumbline Advisers now owns 81,441 shares of the medical equipment provider’s stock worth $2,810,000 after purchasing an additional 3,172 shares during the period. Voce Capital Management LLC acquired a new position in shares of Natus Medical during the 1st quarter worth $22,236,000. Legal & General Group Plc grew its stake in shares of Natus Medical by 6.9% during the 1st quarter. Legal & General Group Plc now owns 69,213 shares of the medical equipment provider’s stock worth $2,314,000 after purchasing an additional 4,496 shares during the period. Finally, Aperio Group LLC grew its stake in shares of Natus Medical by 43.8% during the 1st quarter. Aperio Group LLC now owns 9,481 shares of the medical equipment provider’s stock worth $319,000 after purchasing an additional 2,890 shares during the period. 96.88% of the stock is currently owned by institutional investors and hedge funds.

BABY traded up $0.14 during trading on Friday, hitting $32.01. The stock had a trading volume of 248,818 shares, compared to its average volume of 348,321. The company has a debt-to-equity ratio of 0.29, a quick ratio of 2.19 and a current ratio of 2.99. The stock has a market capitalization of $1.19 billion, a P/E ratio of 22.08 and a beta of 0.59. Natus Medical has a twelve month low of $28.00 and a twelve month high of $43.60.

About Natus Medical

Natus Medical Incorporated provides newborn care, neurology, and hearing and balance assessment healthcare products and services worldwide. It offers products and services used for the screening, diagnosis, detection, treatment, monitoring, and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases, and balance and mobility disorders.

Featured Story: Put Option

Get a free copy of the Zacks research report on Natus Medical (BABY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Natus Medical (NASDAQ:BABY)

Receive News & Ratings for Natus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply